The U.S. Food and Drug Administration (FDA) has approved a request for a supplemental Biologics License Application for the repair of knee cartilage defects using arthroscopic delivery of the autologous cultured chondrocytes on a porcine collagen membrane.
The request was submitted in October of last year under section 351(a) of the Public Health Service Act. The autologous cultured chondrocytes on porcine collagen membrane are marketed under the brand name MACI®.
According to the company that submitted the request, Vericel Corporation, a biopharmaceutical company based in Cambridge, Massachusetts, MACI is “an autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults.” It “applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.”
Furthermore, said the company, the supplemental approval will allow the “arthroscopic delivery of MACI to repair symptomatic single or multiple full-thickness cartilage defects of the knee up to 4 cm2 in size.”
Vericel’s CEO Nick Colangelo said, “The approval of MACI Arthro represents another significant milestone in our strategy to provide innovative solutions for patients suffering from pain and dysfunction caused by cartilage defects in the knee.”
Colangelo continued, “MACI Arthro provides orthopedic surgeons and their patients with a less invasive option for MACI administration, which we believe has the potential to significantly increase penetration into the largest segment of the MACI addressable market and will support sustained top-tier revenue growth for the Company in the years ahead.”
The recently approved MACI Arthro is touted as a less invasive technique when compared to the current method of administration. According to Vericel, MACI Arthro allows “surgeons to evaluate and prepare the defect site as well as deliver the MACI implant through small incisions using custom-designed MACI Arthro instruments.” It is also unique as it is currently the “only restorative biologic cartilage repair product approved for arthroscopic administration.”
They can approve it all they want but no insurance company is going to pay for it. And besides it’s not going to work anyway especially in accident cases and workers compensation
What makes you say that? MACI procedures are already approved by insurance companies and the fact that WC cases and other secondary gain situations “won’t get better” is true of every treatment under the sun, and is not reflective of the general public.
Where is a link to the supporting data? Surely there was some.
May have some benefit in OCD but I doubt any benefit in garden variety OA.